INDICATIONS
BETAGAN has been shown to be effective in lowering intraocular
pressure and may be used in patients with chronic open-angle
glaucoma or ocular hypertension.
DOSAGE AND ADMINISTRATION
The recommended starting dose is one to two drops of BETAGAN
0.5% in the affected eye(s) once a day. Typical dosing with
BETAGAN 0.25% is one to two drops twice daily. In patients
with more severe or uncontrolled glaucoma, BETAGAN 0.5%
can be administered b.i.d. As with any new medication, careful
monitoring of patients is advised. Dosages above one drop
of BETAGAN 0.5% b.i.d. are not generally more effective.
If the patient’s IOP is not at a satisfactory level
on this regimen, concomitant therapy with dipivefrin and/or
epinephrine, and/or pilocarpine and other miotics, and/or
systemically administered carbonic anhydrase inhibitors,
such as acetazolamide, can be instituted. Patients should
not typically use two or more topical ophthalmic beta-adrenergic
blocking agents simultaneously.
HOW SUPPLIED
BETAGAN (levobunolol HCI) Liquifilm sterile ophthalmic solution,
is supplied in white opaque plas-tic dropper bottles as
follows:
BETAGAN 0.25%
C Cap® Compliance Cap BID (twice daily)
5 mL - NDC 11980-469-25
10 mL - NDC 11980-469-20
BETAGAN 0.5%
Standard Cap
2 mL - NDC 11980-252-02
C Cap® Compliance Cap
- Q.D. (once daily)
- 5 mL - NDC 11980-252-65
- 10 mL - NDC 11980-252-60
- 15 mL - NDC 11980-252-61
- BID (twice daily)
- 5 mL - NDC 11980-252-25
- 10 mL - NDC 11980-252-20
- 15 mL - NDC 11980-252-21
NOTE: Protect from light. Store at controlled room
temperature 15°-30°C (59°-86°F)
CAUTION: Federal (USA) law prohibits
dispensing without prescription.
|
